ENARA BIO LIMITED
Operating from the Oxford Science Park, Enara Bio is a private biotechnology company engaged in research and experimental development.
Get an alert when ENARA BIO LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.9m
-31.9% lowest in 3 filed years
Net assets
£9m
-32.6% lowest in 3 filed years
Employees
56
-3.4% vs 2024
Profit before tax
-£18m
-3.4% lowest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
Accordingly, the group and the company are reliant on securing further financing, which is not guaranteed. This indicates that a material uncertainty exists that may cast significant doubt on the group and the company's ability to continue as a going concern, and therefore they may be unable to realise their assets and discharge their liabilities in the normal course of business.
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £17,415,246 | £2,565,725 | £3,030,317 | +18.1% | |
| Operating profit | £1,416,102 | -£17,286,888 | -£17,917,402 | -3.6% | |
| Profit before tax | £1,051,673 | -£17,084,996 | -£17,659,025 | -3.4% | |
| Net profit | £1,337,428 | -£14,533,712 | -£15,032,521 | -3.4% | |
| Cash | £11,863,604 | £4,246,352 | £2,890,817 | -31.9% | |
| Total assets less current liabilities | £10,237,013 | £13,352,288 | — | — | |
| Net assets | £10,237,013 | £13,352,288 | £8,998,767 | -32.6% | |
| Equity | £10,237,013 | £13,352,288 | £8,998,767 | -32.6% | |
| Average employees | 54 | 58 | 56 | -3.4% | |
| Wages | £5,958,094 | £6,811,641 | £6,445,313 | -5.4% | |
| Directors' remuneration | £612,124 | £673,348 | £773,555 | +14.9% | |
| Directors' pension contributions | £25,773 | — | £17,199 | — | |
| Highest paid director | £587,945 | £645,953 | £660,985 | +2.3% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 8.1% | — | — | |
| Net margin | 7.7% | — | — | |
| Return on capital employed | 13.8% | -129.5% | — | |
| Gearing (liabilities / total assets) | 34.0% | 0.0% | — | |
| Current ratio | 2.53x | 5.24x | 3.36x | |
| Interest cover | 2.81x | — | — |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- ENARA BIO LIMITED 2020-06-03 → present
- ERVAXX LIMITED 2016-11-08 → 2020-06-03
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Consolidated group
- Auditor
- BDO LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“Accordingly, the group and the company are reliant on securing further financing, which is not guaranteed. This indicates that a material uncertainty exists that may cast significant doubt on the group and the company's ability to continue as a going concern, and therefore they may be unable to realise their assets and discharge their liabilities in the normal course of business.”
Group structure
- ENARA BIO LIMITED · parent
- Enara Bio Inc. 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
8 active · 4 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| AL-HALLAQ, Rana Abdul Raouf, Dr | Director | 2024-08-29 | Jun 1975 | American |
| ANG, Robert Yuen Lee, Dr | Director | 2021-09-21 | Apr 1974 | American,Australian |
| ANNINGA, Bauke, Dr | Director | 2024-08-29 | Dec 1986 | Dutch |
| BINGHAM, Catherine Elizabeth, Dame | Director | 2023-06-14 | Oct 1965 | British |
| DYBBS, Michael Philip | Director | 2020-04-27 | Dec 1974 | American |
| POJASEK, Kevin Robert | Director | 2018-09-01 | Feb 1976 | American |
| RESNICK, Joshua Benjamin | Director | 2020-04-27 | Dec 1974 | American |
| WOOD, Clive Ross | Director | 2025-03-01 | Dec 1960 | American |
Show 4 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| ASHRAFIAN, Houman, Professor | Director | 2016-11-08 | 2023-06-14 |
| BINGHAM, Catherine Elizabeth | Director | 2017-02-01 | 2020-04-27 |
| DINES, Jonathon Alan | Director | 2016-11-08 | 2017-05-19 |
| EDWARDS, Timothy Peter Warren | Director | 2017-04-04 | 2020-04-27 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Rajeev Shah | Individual | Voting 25–50% | 2020-04-27 | Ceased 2024-08-30 |
| Peter Kolchinsky | Individual | Voting 25–50% | 2020-04-27 | Ceased 2024-08-30 |
| Professor Houman Ashrafian | Individual | Shares 75–100%, Voting 25–50% | 2016-11-08 | Ceased 2017-12-18 |
Filing timeline
Last 20 of 130 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-03-03 MA Memorandum articles
- 2026-03-03 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-09-14 | AA | accounts | Accounts with accounts type group | |
| 2026-09-09 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-06-19 | SH01 | capital | Capital allotment shares | |
| 2026-05-22 | SH01 | capital | Capital allotment shares | |
| 2026-05-15 | SH10 | capital | Capital variation of rights attached to shares | |
| 2026-05-15 | SH08 | capital | Capital name of class of shares | |
| 2026-03-12 | SH01 | capital | Capital allotment shares | |
| 2026-03-03 | MA | incorporation | Memorandum articles | |
| 2026-03-03 | RESOLUTIONS | resolution | Resolution | |
| 2025-11-10 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-11-06 | CH01 | officers | Change person director company with change date | |
| 2025-11-03 | SH01 | capital | Capital allotment shares | |
| 2025-08-28 | AA | accounts | Accounts with accounts type group | |
| 2025-08-27 | SH01 | capital | Capital allotment shares | |
| 2025-08-14 | SH01 | capital | Capital allotment shares | |
| 2025-05-13 | SH01 | capital | Capital allotment shares | |
| 2025-05-06 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2025-05-06 | RP04SH01 | capital | Second filing capital allotment shares | |
| 2025-03-19 | AP01 | officers | Appoint person director company with name date | |
| 2025-03-13 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 12
- Capital events
- 12
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.